BioAdaptives

BioAdaptives Debt/EBITDA

The Total Debt to EBITDA Ratio of BioAdaptives (BDPT) as of Oct 25, 2026 is -0.37. In the previous year, Total Debt to EBITDA Ratio was -0.57 — a change of -35.48% (higher).

Debt/EBITDA

-0.37

YoY

-35.48%

Last updated:

Total Debt to EBITDA Ratio of BioAdaptives is 2025 -0.37 . Total Debt to EBITDA Ratio of BioAdaptives was 2024 -0.57 . It decreases by -35.48% higher compared to the previous year.

The BioAdaptives Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2018
-0.13 USD
Jan 1, 2019
-1.58 USD
Jan 1, 2020
-1.90 USD
Jan 1, 2021
-0.87 USD
Jan 1, 2022
-1.09 USD
Jan 1, 2023
-1.64 USD
Jan 1, 2024
-0.57 USD
Jan 1, 2025
-0.37 USD
The BioAdaptives Debt/EBITDA history
YEARDebt/EBITDAYoY
-0.37-35.48%
-0.57-65.12%
-1.64+50.45%
-1.09+25.27%
-0.87-54.19%
-1.90+20.27%
-1.58+1,083.04%
-0.13—
0.00—
0.00—
0.00-100.00%
-0.01—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioAdaptives Stock analysis

What does BioAdaptives do? BioAdaptives, Inc. generates revenue through the sale of health and wellness products including dietary supplements, specialty food items, and devices that optimize bioelectromagnetic availability. The company markets PrimiCell and PrimiLive under a product agreement with Ferris Holding, Inc., targeting consumers seeking cognitive enhancement, fatigue reduction, and anti-aging solutions. PrimiTrim serves the weight control segment, while Equine Regen and Equine Regen Plus are in advanced testing for veterinary use. The firm also develops a dog product, expanding its wellness offerings across human and animal health markets. Ferris Holding, Inc. provides the intellectual property and products that BioAdaptives markets, including PrimiCell and PrimiLive, which are positioned for cognition, focus, and emotional wellness. The company's advanced-stage products Equine Regen and Equine Regen Plus cater to the veterinary segment, with PrimiTrim addressing weight management needs. BioAdaptives' product portfolio spans nutraceuticals, devices, and specialty foods designed to improve physical and emotional wellness across multiple consumer segments. BioAdaptives focuses on selling devices and nutraceuticals that target cognitive performance, fatigue reduction, and anti-aging, with PrimiCell and PrimiLive as key products under the Ferris agreement. The company's weight control solution PrimiTrim appeals to consumers seeking wellness through diet, while Equine Regen and Equine Regen Plus target animal health providers. The firm's development of a dog product further diversifies its offerings in the wellness market. BioAdaptives is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioAdaptives stock

Total Debt to EBITDA Ratio of BioAdaptives is -0.37 in 2025.

Total Debt to EBITDA Ratio of BioAdaptives changed from -0.57 to -0.37, representing a -35.48% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio BioAdaptives since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's BioAdaptives with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — BioAdaptives

All Key Metrics — BioAdaptives